Videos

Michael Kolodziej, MD,  talks about who would benefit in attending such conferences, and some of the takeaways from such meetings.

Gary Palmer, MD, JD, MBA, MPH talks about the challenges related to costs facing community oncologists and some of the consequences of it.

Michael Kolodziej, MD, talks about how oncologists' perspectives have changed to understand that cost and quality do not have to be at odds with one another.

Gary Palmer, MD, JD, MBA, MPH points out the value for oncologists, industry, and the payers to know where oncology is going in order to stay current of the trends and its future.

Dr Edward Garon provides an overview of the main concerns he has in managing patients with NSCLC, citing pseudoprogression as one of the biggest misconceptions.

Dr Suresh Ramalingam discusses the importance of screening for lung cancer and identifies the ideal patients to target for screening.

Dr Suresh Ramalingam examines the factors he considers when making treatment decisions for his patients.

Although Dr Edward Garon feels the future of NSCLC is unclear, he cites how treatment has progressed over the years and wonders how immunotherapies and combination therapies will impact treatment.

Gary Palmer, MD, JD, MBA, MPH discusses some of the ways in which this branch of molecular biology is used in developing cancer therapies.

Gary Palmer, MD, JD, MBA, MPH provides an overview of this significant federal initiative.